Details

Autor(en) / Beteiligte

• Colombo, D
• Maggioni, AP
• Cinconze, E
• Rossi, E
• Nica, M

Titel

GENDER DIFFERENCES IN HEART FAILURE IN A REAL WORLD CONTEST: IMPACT ON DRUG UTILIZATION AND COSTS FOR THE MANAGEMENT OF THIS CLINICAL CONDITION

Ist Teil von

• Value in health, 2017-05, Vol.20 (5), p.A367

Ort / Verlag

Lawrenceville: Elsevier Science Ltd

Erscheinungsjahr

2017

Quelle

Applied Social Sciences Index & Abstracts (ASSIA)

Beschreibungen/Notizen

• OBJECTIVES: Heart failure has a high burden of morbidity and mortality, which imply substantial healthcare costs. It is the main hospitalization cause in eailerly patients. Gender is important risk factor for CV diseases. Using data from a large Italian database, we analyzed drug utilization and healthcare costs of managing HF from a gender prospective, in a "real world" scenario. METHODS: Data from "Osservatorio ARNO Cineca". This report reffers to a sample of 54,059 patients with heart failure, for whom hospitalizations, specialistic visits, and drug prescriptions, were available. Re-hospitalizations were analysed and costs were evaluated using Italian tariffs during the 1-year follow-up period: drugs, diagnostic and therapeutic procedures, hospitalizations. Mean cost was calculated per patient per year for 1-year follow-up or until death. Gender analysis were performed for a number of variables including drugs use and healthcare costs. RESULTS: Women medium age was 80.4 years (±10.1) and men 75.5 (±11.4). Distribution by age was different in the two genders: only 25% of women developed CHF before age 75, while 43% of men had CHF before age 75. Hospital admissions were major determinant of costs for management of HF and were analyzed from a gender prospective. Women were more likely to be admitted to general medicine services, while men to cardiology units. 54.6% and 15.2% of women were hospitalized in "General medicine" or "Geriatrics", compared to 44.6% and 12.0% of men, respectively. Only 16.3% and 4.3% of women are admitted to "Cardiology" or "Coronary Heart Disease" units, compared to 23.5% and 9.4% of men, respectively. Men were more likely prescribed ACE-i or ARBs and BB. CONCLUSIONS: Our data confirm, in a real world setting that gender makes difference in CV diseases. Moreover, costs for NHS are mainly driven by hospital costs and patient gender seems to influence them, so it must be taken into account.